TrialCancer medicine2020

Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib.

Imane El Dika et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.